S.MilesL.ReaumeJ.et al (2011)
Cureus 14 , e26916 (2022)
Mechanism Diagram GHK-Cu vs Growth Peptides (Key Differences) GHK-Cu - Copper binding tripeptide - Acts locally in tissue - Modulates gene expression and ECM remodelling - Not endocrine - Does not elevate GH or IGF-1 GH Secretagogues (e.g., Ipamorelin, Hexarelin, MK-677) - Act via endocrine receptors - Stimulate systemic GH release - Increase IGF-1 - Primarily hormonal These compounds operate in completely different biological domains
If side effects feel intolerable at your current dose, your provider may pause at that level for an additional two to four weeks before advancing further
This data becomes invaluable when deciding whether to escalate, hold, or reduce a dose
Integrated Mechanistic Research Framework The combined architecture of KLOW70 allows researchers to examine: Extracellular matrix signaling coordination Gene expression pathway interaction Immune signaling cascade modeling Nitric oxide system research Multi-peptide synergy investigations All mechanistic evaluations must be conducted within regulated laboratory environments